Hirota M, Hidaka E, Ueno I, Ishikawa M, Asano N, Yamauchi K, Ishida F, Tozuka M, Katsuyama T
Central Clinical Laboratories, Shinshu University Hospital, Asahi, Matsumoto, Japan.
Br J Haematol. 2000 Sep;110(4):867-70. doi: 10.1046/j.1365-2141.2000.02205.x.
In a patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL), a novel variant of the chimaeric BCR-ABL mRNA transcript was detected by reverse transcription polymerase chain reaction (RT-PCR). Sequencing revealed the novel transcript to be a chimaeric mRNA produced by fusion of the BCR exon 14 (b3) to the ABL exon a2 with a 49-base pair (bp) insertion of an ABL intron 1b sequence between them. The insertion of the 49 bp introduced a stop codon. These data show that this variant of the chimaeric mRNA would not be translated into the p210 BCR-ABL protein. This could be one of the explanations as to why clinically the patient has responded well to therapy and continues to follow a mild clinical course.
在一名费城染色体阳性急性淋巴细胞白血病(ALL)患者中,通过逆转录聚合酶链反应(RT-PCR)检测到一种新的嵌合型BCR-ABL mRNA转录变体。测序显示该新转录本是一种嵌合型mRNA,由BCR外显子14(b3)与ABL外显子a2融合产生,两者之间插入了一段49个碱基对(bp)的ABL内含子1b序列。这49 bp的插入引入了一个终止密码子。这些数据表明,这种嵌合型mRNA变体不会被翻译成p210 BCR-ABL蛋白。这可能是该患者在临床上对治疗反应良好且病情持续处于轻度临床进程的原因之一。